Our results also indicate that immunomodulatory drug treatment modulates the tumor‐immune landscape by reducing the amount and frequency of macrophages and partly increasing the frequency of CD11b+ cells, which are not macrophages, within our multicellular 3D model. This evidence concerns the gene ITGAM and neoplasm.